Search Results

Efficacy of rifaximin against covert hepatic encephalopathy and hyperammonemia in Japanese patients

• Authors : Nakai, Masato; Suda, Goki; Ogawa, Koji

• Source: PLoS ONE. July 1, 2022, Vol. 17 Issue 7, e0270786

Record details

Affiliated Drum Tower Hospital of Nanjing University Medical School Researcher Updates Current Study Findings on Hepatic Encephalopathy (Efficacy of transjugular intrahepatic portosystemic shunt in treatment of primary biliary cholangitis with ...)

• Source: Cardiovascular Week. March 27, 2023, 110

Record details

Rifaximin: a nonabsorbable, broad-spectrum antibiotic for reduction in the risk for recurrence of overt hepatic encephalopathy.

• Authors : Feret, Brett; Barner, Benjamin

• Source: Formulary. 2010, Vol. 45, Issue 7, pages. 7

Record details

BRIEF SUMMARY OF PRESCRIBING INFORMATION

• Source: Medical Economics. February, 2021, Vol. 98 Issue 2, p34, 1 p.

Record details

Rifaximin treatment in hepatic encephalopathy

• Authors : Bass, Nathan M.; Mullen, Kevin D.; Sanyan, Arun

• Source: The New England Journal of Medicine. March 25, 2010, Vol. 362 Issue 12, p1071, 11 p.

Record details

Agricola

Record details

Hyperion clinical data (Phase II) (cirrhosis, hepatic encephalopathy).

• Source: R & D Focus Drug News. 2012.

Record details

Salix marketed, USA (hepatic encephalopathy).

• Source: R & D Focus Drug News. 2010.

Record details

Hyperion phase change II, Europe, USA (hepatic encephalopathy).

• Source: R & D Focus Drug News. 2009.

Record details

rifaximin Salix files NDA for hepatic encephalopathy.

• Source: R & D Focus Drug News. 2009.

Record details